TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Phase 1
Active, not recruiting
- Conditions
- Pediatric Cancer
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Orphelia Pharma
- Target Recruit Count
- 49
- Registration Number
- NCT04610736
- Locations
- 🇳🇱
Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands
🇫🇷Institut Curie, Paris, France
🇫🇷Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration
Phase 1
Completed
- Conditions
- Therapeutic Equivalency
- Interventions
- Drug: VGB-ST
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Orphelia Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT04468282
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Orphelia Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT04467346
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷Hôpital de la Timone (AP-HM), Marseille, France
🇫🇷Service de neuro-oncologie - Hospices Civils de Lyon, Bron, Rhône, France
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
Not Applicable
Completed
- Conditions
- Infantile Spasms
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Orphelia Pharma
- Target Recruit Count
- 38
- Registration Number
- NCT02220114
- Locations
- 🇫🇷
Service de nuerologie pédiatrique - Hôpital Femme Mère Enfant, Lyon, France
🇫🇷Service de neurologie pédiatrique - CHU, Angers, France
🇫🇷Service de neuropédiatrie - CHU Pellegrin Enfants, Bordeaux, France
© Copyright 2025. All Rights Reserved by MedPath